BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025
• 2026

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 3
• 4
• 5
• 6
• 7
• 8
• 9
• 10
• 11
• 12
• 13
• 14
• 15
• 16
• 17
• 19
• 20
• 21
• 22
• 23
• 24
• 26
• 27
• 28
• 29
• 30

• Business

  Madrigal Pharmaceuticals Reports 2017 Third Quarter Financial Results

  Top-line results from MGL-3196 Phase 2 clinical trials in NASH and HeFH expected in late 2017 and early 2018, respectively.

  November 9, 2017

   · 

  9 min read
• Drug Development

  Idera Pharmaceuticals Presents Positive Translational and Clinical Data Update from Ongoing IMO-2125 Development Program at the 2017 Society for Immunotherapy of Cancer Annual Meeting (SITC)

  These data will be presented at 4:45 P.M. E.T. on Saturday, November 11th.

  November 9, 2017

   · 

  8 min read
• Business

  iCAD Announces Positive Clinical Data on Xoft System for Non-Melanoma Skin Cancer Treatment Selected as “Best of ASTRO 2017”

  Best of ASTRO meeting recognizes most relevant and highly influential research at ASTRO 2017.

  November 9, 2017

   · 

  4 min read
• Drug Development

  Iovance Biotherapeutics Announces New LN-144 Phase II Clinical Data from Metastatic Melanoma Trial to be Presented at SITC Meeting

  The data shows that administration of the company’s Generation 2 (Gen 2) manufacturing process in nine efficacy-evaluable metastatic melanoma patients resulted in a disease control rate (DCR) of 78%, which includes 3 confirmed partial responders (PRs) and a fourth PR awaiting confirmation.

  November 9, 2017

   · 

  7 min read
• Drug Development

  TRACON Pharmaceuticals Presents Updated Data from Phase Ib/II Study of TRC105 and Votrient® in Patients with Soft Tissue Sarcoma Including Angiosarcoma

  Combination treatment continues to demonstrate encouraging signs of activity.

  November 9, 2017

   · 

  5 min read
• Drug Development

  Vascular Therapies Announces Preliminary Results From its Phase III AV Fistula Study

  Vascular Therapies presented preliminary results relating to analysis of the first 18 patients from its US Phase III study.

  November 9, 2017

   · 

  3 min read
• BioMidwest

  New Post-Hoc Analysis Evaluating Deep Remission With Entyvio (vedolizumab) in Patients With Moderately to Severely Active Ulcerative Colitis Recognized as Poster of Distinction at AIBD 2017 Annual Conference

  The poster was selected as a “Poster of Distinction” for presentation at the 2017 AIBD annual conference, held in Orlando, Florida, November 9-11.

  November 9, 2017

   · 

  10 min read
• Drug Development

  Immuron Successfully Completes NASH Phase II Clinical Study Milestone

  The last patient in the Company’s NASH clinical study conducted the final scheduled visit on October 9, following a 28-week study period.

  November 9, 2017

   · 

  6 min read
• Deals

  PharMerica Announces Approval of Merger by Stockholders

  The closing of the transaction remains subject to customary closing conditions.

  November 9, 2017

   · 

  5 min read
• Genetown

  Navitor Pharmaceuticals’ Scientific Founder Makes Seminal Discoveries Related to Role of Nutrient Sensors in mTOR Regulation and Activity

  Today, Dr. Sabatini published in the journal Science the discovery of a new nutrient sensor in the mTORC1 pathway, SAMTOR

  November 9, 2017

   · 

  5 min read